Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A2044 | Omalizumab (anti-IgE) | Omalizumab is a recombinant, humanised, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research. | Human IgG1 |
| A2337 | Concizumab (Anti-TFPI) | Concizumab (Anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. MW: 145.5 KD. | Human IgG4SP |
| A2593 | Enibarcimab (Anti-Adrenomedullin) | Enibarcimab (Anti-Adrenomedullin) is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody targeting the vasoprotective peptide adrenomedullin. It can be used for acute heart failure, COVID-19 infections and septic shock research. MW: 145.5 KD. | Human IgG1 |
| A2338 | Ontuxizumab (Anti-TEM1 / Endosialin / CD248) | Ontuxizumab (Anti-TEM1/endosialin/ CD248) is a humanised IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with potential anti-angiogenic and antineoplastic activities. MW : 145.5 KD | Human IgG1 |
| A2594 | Ascrinvacumab (Anti-ACVRL1 / ALK-1) | Ascrinvacumab (Anti-ACVRL1 / ALK-1) is a human IgG2 monoclonal antibody targeting ALK-1. It can be used for the treatment of hepatocellular carcinoma (HCC), in patients with advanced solid tumours. It also demonstrates its use in antiangiogenic therapy. MW: 150 KD. | Human IgG2SA |
| A2339 | Anti-TCR | Anti-TCR is a monoclonal antibody targeting TCR. MW: 145.5 KD. | Human IgG2SA |
| A2595 | Bimagrumab (Anti-ACVR2B) | Bimagrumab (Anti-ACVR2B) is a human monoclonal antibody targeting activin type II receptor (ActRII). It can be used for the treatment of pathological muscle loss and weakness. MW : 150 KD. | Human IgG1 |
| A2340 | Anti-TBFbR2 | Anti-TBFbR2 is a monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. MW: 145.5 KD | Human IgG1 |
| A2341 | Zagotenemab (Anti-Tau) | Zagotenemab (Anti-Tau) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. It has the potential to be used in Alzheimer's disease research. MW: 145.5 KD | Human IgG4SP |
| A2342 | Indatuximab (Anti-Syndecan-1 / CD138) | Indatuximab (Anti-Syndecan-1/CD138) is an antibody against Syndecan-1. MW : 145.5 KD | Human IgG4SP |
| A2343 | Vandortuzumab (Anti-STEAP1) | Vandortuzumab (Anti-STEAP1) is a recombinant monoclonal antibody that specifically targets STEAP1. It has potential for the treatment of prostate cancer. MW : 145.5 KD. | Human IgG1 |
| A2344 | Bexmarilimab (Anti-STAB1) | Bexmarilimab (Anti-STAB1) is a monoclonal antibody directed against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1; stabilin-1; FEEL-1) with an IC50 value of 4.51 nM and potential immunomodulatory and antineoplastic activities. MW : 145.5 KD. | Human IgG4SP |
| A2345 | Sonepcizumab (Anti-Sphingosine-1-phosphate) | Sonepcizumab (Anti-Sphingosine-1-phosphate) is a humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. MW : 145.5 KD. | Human IgG1 |
| A2347 | Sirtratumab (Anti-SLITRK6) | Sirtratumab (Anti-SLITRK6) is a humanized Igγ2 monoclonal antibody against SLIT and NTRK-like family 6 (Slitrk6). MW: 145.5 KD. | Human IgG2SA |
| A2348 | Anti-SLC44A4 | Anti-SLC44A4 is a fully human IgG2k monoclonal antibody targeting SLC44A4 (AGS-5) with potential antineoplastic activity. MW: 145.5 KD. | Human IgG2SA |
| A2349 | Anti-SLC40A1 | Anti-SLC40A1 is a monoclonal antibody targeting SLC40A1. It has the potential to do research on mineral absorption, insulin receptor recycling, and Transmembrane Transporters activity. MW : 145.5 KD. | Human IgG4SP |
| A2350 | Lifastuzumab (Anti-SLC34A2) | Lifastuzumab (Anti-SLC34A2) is a humanised monoclonal antibody targeting NaPi2b. MW : 145.5 KD. | Human IgG1 |
| A2040 | Leronlimab (anti-CCR5) | Leronlimab (anti-CCR5) (PRO 140; Vyrologix) is a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. It is being investigated as a potential therapy in the treatment of HIV infection. | Human IgG4 |
| A2351 | Upifitamab (Anti-SLC34A2) | Upifitamab (Anti-SLC34A2) is a humanised monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesise an ADC compound, Upifitamab rilsodotin, used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer. MW : 145.5 KD. | Human IgG1 |
| A2352 | Idactamab (Anti-SLC1A5 / ASCT2) | Idactamab (Anti-SLC1A5 / ASCT2) is an IgG1-κ antibody with in vivo activity across a spectrum of haematological malignancies. Idactamab can be used to prepare MEDI7247, a potent and specific ADC targeting ASCT2 (SLC1A5). MW: 145.5 KD. | Human IgG1 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.